Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine

Pool, Martin; Boer, H. Rudolf de; Hooge, Marjolijn N. Lub-de; Vugt, Marcel A.T.M. van; Vries, Elisabeth G.E. de

doi:10.7150/thno.17934

Cited by 9 publications

(7 citation statements)

References 185 publications

(215 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epidermal growth factor receptor (EGFR) is one of four transmembrane receptor tyrosine kinases within the human epidermal growth factor receptor (HER) family. By homo-or heterodimerization with other family members, EGFR modulates cellular growth, survival, adhesion, migration and differentiation [1,2]. Aberrant EGFR expression and/or activation has been described in many epithelial tumors such as head and neck squamous cell carcinoma (HNSCC), breast, lung, ovary, bladder, prostate, kidney cancer and glioma [3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

PET imaging of EGFR expression using an 18F-labeled RNA aptamer

Cheng

Jacobson

Zhu

et al. 2018

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

PET imaging of EGFR expression using an 18F-labeled RNA aptamer

Cheng

Jacobson

Zhu

et al. 2018

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…In the past study, GSH metabolism was thought to be one major mechanism of chemo-resistance in the NSCLC. 16 In addition, Pool et al 17 deemed that the GSK metabolism pathway might be essential for tumor response to EGFR-TKI afatinib alone or combined with Rapamycin. Presently, EGFR-TKIs are effective in the lung cancer patients who have a deletion mutation of exon 19 and L858R mutation of exon 21.…”

Section: Discussionmentioning

confidence: 99%

An Integrative Transcriptomic Analysis Reveals EGFR Exon-19 E746-A750 Fragment Deletion Regulated miRNA, circRNA, mRNA and lncRNA Networks in Lung Carcinoma

Chen¹,

Li²,

Shi³

et al. 2022

IJGM

View full text Add to dashboard Cite

Competing endogenous RNA (ceRNA) appears to be an important post-transcriptional manner that regulates gene expression through a miRNA-mediated mechanism. Mutations in exon-19 of EGFR were frequently observed in lung cancer genes, which were associated with EGFR activity and EGFR-targeted therapies. Methods: We explored the transcriptome regulated by mutation in EGFR exon-19 E746-A750 fragment via using a network modeling strategy. We applied transcriptome sequencing to detect the deletion process of EGFR exon-19 E746-A750 fragment. Bioinformatics analyses were used to predict the gene target pairs and explain their potential roles in tumorigenesis and progression of lung cancer. Results:We conducted an explorative lncRNA/miRNA/circRNA and mRNA expression study with two groups of lung adenocarcinoma tissues, including EGFR exon-19 E746-A750 deletion group and EGFR exon-19 wild-type group. Meanwhile, we screen out the hub genes related to the EGFR-19-D patient. Significant pathways and biological functions potentially regulated by the deregulated 128 non-coding genes were enriched. Conclusion:Our work provides an important theoretical, experimental and clinical foundation for further research on more effective targets for the diagnosis, therapy and prognosis of lung cancer.

show abstract

“…Indeed, mAbs and small-molecule tyrosine kinase inhibitors (TKIs) suppressing RTKs or their ligands are the most typical examples of targeted cancer therapies. Along with this success, substantial efforts have been dedicated to developing immunoPET imaging approaches for revealing the heterogeneous status of RTKs in cancers …”

Section: Immunopet Imaging Of Cancersmentioning

confidence: 99%

ImmunoPET: Concept, Design, and Applications

et al. 2020

View full text Add to dashboard Cite

Immuno-positron emission tomography (immunoPET) is a paradigmshifting molecular imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) and the inherent sensitivity of PET technique. A variety of radionuclides and mAbs have been exploited to develop immunoPET probes, which has been driven by the development and optimization of radiochemistry and conjugation strategies. In addition, tumor-targeting vectors with a short circulation time (e.g., Nanobody) or with an enhanced binding affinity (e.g., bispecific antibody) are being used to design novel immunoPET probes. Accordingly, several immunoPET probes, such as 89 Zr-Df-pertuzumab and 89 Zr-atezolizumab, have been successfully translated for clinical use. By noninvasively and dynamically revealing the expression of heterogeneous tumor antigens, immunoPET imaging is gradually changing the theranostic landscape of several types of malignancies. ImmunoPET is the method of choice for imaging specific tumor markers, immune cells, immune checkpoints, and inflammatory processes. Furthermore, the integration of immunoPET imaging in antibody drug development is of substantial significance because it provides pivotal information regarding antibody targeting abilities and distribution profiles. Herein, we present the latest immunoPET imaging strategies and their preclinical and clinical applications. We also emphasize current conjugation strategies that can be leveraged to develop next-generation immunoPET probes. Lastly, we discuss practical considerations to tune the development and translation of immunoPET imaging strategies.

show abstract

Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine

Cited by 9 publications

References 185 publications

PET imaging of EGFR expression using an 18F-labeled RNA aptamer

PET imaging of EGFR expression using an 18F-labeled RNA aptamer

An Integrative Transcriptomic Analysis Reveals EGFR Exon-19 E746-A750 Fragment Deletion Regulated miRNA, circRNA, mRNA and lncRNA Networks in Lung Carcinoma

ImmunoPET: Concept, Design, and Applications

Contact Info

Product

Resources

About